Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed May 20, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Cash from operations

Big change, FY to Mar 28, 2026 vs Mar 29, 2025

+61.4%

The MD&A has no sentence that names a cause for this change.

Operating margin

Big change, FY to Mar 28, 2026 vs Mar 29, 2025

16.3% to 11.7% (-4.6 pts)

The MD&A has no sentence that names a cause for this change.

Net income

Big change, FY to Mar 28, 2026 vs Mar 29, 2025

-42.0%

The MD&A has no sentence that names a cause for this change.

Gross margin

Big change, FY to Mar 28, 2026 vs Mar 29, 2025

55.0% to 59.0% (+4.0 pts)

The MD&A has no sentence that names a cause for this change.

Revenue

Change, FY to Mar 28, 2026 vs Mar 29, 2025

-2.0%

“This revenue decrease was primarily driven by lower sales volumes in North America relating to the previously announced customer transition of CSL Plasma, partially offset by share gains, higher volume and pricing benefits.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2026 -2.0%

    “This revenue decrease was primarily driven by lower sales volumes in North America relating to the previously announced customer transition of CSL Plasma, partially offset by share gains, higher volume and pricing benefits.”

    Read it in the FY 2026 10-K
  • FY 2025 +4.0%

    “This revenue decrease was primarily driven by lower sales volumes in North America, entirely relating to the previously announced customer transition of CSL Plasma.”

    Read it in the FY 2025 10-K

    “The decrease in Blood Center’s reported revenue was primarily driven by declines in our Whole Blood business, which was divested in the fourth quarter of fiscal 2025.”

    Read it in the FY 2025 10-K

Gross margin

0 of 2 years explained
  • FY 2026 +4.0 pts

    The FY 2026 MD&A has no sentence that names a cause for this change.

  • FY 2025 +2.2 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

Operating margin

1 of 2 years explained
  • FY 2026 -4.6 pts

    The FY 2026 MD&A has no sentence that names a cause for this change.

  • FY 2025 +3.7 pts

    “Operating income increased 34.5% during fiscal 2025 as compared with fiscal 2024, primarily due to operating leverage, the remeasurement of contingent consideration, decreased performance-based compensation and the gain realized on the sale of a manufacturing facility in the first quarter of fiscal 2025, partially offset by operating, transaction and integration costs related to recent acquisitions, increased amortization of acquired intangible assets and amortization of fair value inventory step-up.”

    Read it in the FY 2025 10-K

Net income

1 of 2 years explained
  • FY 2026 -42.0%

    The FY 2026 MD&A has no sentence that names a cause for this change.

  • FY 2025 +42.6%

    “Our effective tax rate for the year ended March 29, 2025 is lower than our effective tax rate of 22.6% for fiscal 2024, primarily due to the favorable impact of contingent consideration remeasurement and the expiration of the statute of limitations associated with uncertain tax position reserves, partially offset by the impact of the jurisdictional mix of earnings.”

    Read it in the FY 2025 10-K

    “Operating cash for fiscal year 2025 benefited from higher net income, lower accounts receivable and decreased accrued performance-based compensation, as compared to the fiscal 2024 period, partially offset by non-cash items including the remeasurement of contingent consideration and gains on the repurchase of convertible senior notes and sales of property, plant and equipment.”

    Read it in the FY 2025 10-K

Cash from operations

0 of 2 years explained
  • FY 2026 +61.4%

    The FY 2026 MD&A has no sentence that names a cause for this change.

  • FY 2025 -0.0%

    The FY 2025 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.